Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy
- 5 March 2017
- journal article
- research article
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 33 (6) , 690-695
Abstract
Background: Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (CRS-HIPEC) prolongs survival in patients with metastatic peritoneal disease. We look at the incidence of acute kidney injury (AKI) in patients who have received cisplatin during CRS-HIPEC in the treatment of peritoneal carcinomatosis from an ovarian primary, and identify possible peri-operative risk factors. Methods: Between 2005 and 2013, we performed CRS-HIPEC on 47 patients with ovarian primaries and peritoneal metastasis. Retrospective data were collected on the patient’s demographics, treatment details and outcomes. Renal impairment was graded according to the NCI-CTCAE 3.0 criteria. Results: There were 47 patients, with a median age of 50 (24–74) years. The median baseline creatinine was 53 μmol/L (23–102) and median baseline albumin of 39 g/L (13–45). All underwent pre-operative chemotherapy for a median of six cycles (0–22) with a median of 15 days between chemotherapy and surgery. They received intra-operative cisplatin at a temperature of 40 °C for 60 min at a median dose of 90 mg/kg. 19 (40.4%) experienced post-operative AKI, of which 5 (8.5%) developed grade 3 and 4 impairment. Two (4.3%) required long-term dialysis. Univariate analysis showed that risk factors for AKI included age, baseline creatinine, baseline estimated glomerular filtration rate, pre-operative albumin, number of cycles of pre-operative carboplatin, time interval between pre-operative chemotherapy and CRS-HIPEC and volume of blood transfusions. Conclusions: Identification of risk factors for AKI post-CRS-HIPEC helps improve pre-operative patient selection and optimisation, facilitate tailoring of chemotherapy, and foster closer peri-operative monitoring and fluid management in at-risk patients.Keywords
This publication has 14 references indexed in Scilit:
- Complications and Toxicities After Cytoreductive Surgery and Hyperthermic Intraperitoneal ChemotherapyAnnals of Surgical Oncology, 2013
- Transfusion and risk of acute kidney injury in cardiac surgeryBritish Journal of Anaesthesia, 2012
- Risk Factors for Perioperative Acute Kidney Injury After Adult Cardiac Surgery: Role of Perioperative ManagementThe Annals of Thoracic Surgery, 2012
- Pharmacogenomics of Cisplatin-Based Chemotherapy in Ovarian Cancer Patients of Different Ethnic OriginsPharmacogenomics, 2012
- Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Systemic ToxicityAnnals of Surgical Oncology, 2007
- New-generation platinum drugs in the treatment of cisplatin-resistant cancersExpert Opinion on Investigational Drugs, 2005
- Cisplatin-Associated Nephrotoxicity and Pathological Events2005
- Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis From Colorectal Cancer: A Multi-Institutional StudyJournal of Clinical Oncology, 2004
- Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal CancerJournal of Clinical Oncology, 2003
- Peritonectomy ProceduresAnnals of Surgery, 1995